Doctor Arthur Mader
VIVIT Institute, Feldkirch (Austria)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
/f/125658/5000x1496/8aa45c8224/eacvi-acronym-text-rgb.png)
Three decades of lipid-lowering therapy in type 2 diabetic patients with angiographically proven stable coronary artery disease
Event: ESC Congress 2024
Topic: Pharmacotherapy
Session: Medical and percutaneous treatment of coronary artery disease
Cystatin C predicts cardiovascular events in patients with coronary artery disease both among patients with and among those without type 2 diabetes
Event: ESC Congress 2024
Topic: Biomarkers
Session: Novel biomarkers for cardiovascular risk prediction
Remnant cholesterol predicts major cardiovascular events in coronary artery disease patients with NAFLD
Event: ESC Congress 2024
Topic: Lipids
Session: Lipoproteins and cardiovascular risk
The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes
Event: ESC Congress 2019
Topic: Biomarkers
Session: Diabetes and the heart
Serum ceramides and type 2 diabetes are mutually independent predictors of cardiovascular events in patients with peripheral artery disease
Event: ESC Congress 2019
Topic: Biomarkers
Session: Vascular disease
